Adjuvant Lung Cancer – Roy Herbst, MD, and Robert Figlin, MD, discuss the recent ASCO20 plenary presentation of the ADAURA study investigating the use of Tagrisso (osimertinib) in stage I-III EGFR+ NSCLC patients

Adjuvant Lung Cancer – Roy Herbst, MD, and Robert Figlin, MD, discuss the recent ASCO20 plenary presentation of the ADAURA study investigating the use of Tagrisso (osimertinib) in stage I-III EGFR+ NSCLC patients

Thursday June 25, 2020

Roy Herbst, MD, and Robert Figlin, MD, discuss the implications of the ADAURA study investigating the use of Tagrisso (osimertinib) in stage I-III EGFR+ NSCLC patients

Prostate Cancer – Robert Figlin, MD, and Neeraj Agarwal, MD, discuss clinical progress in prostate cancer

Monday February 22, 2021

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Neeraj Agarwal, MD, Professor of Medicine, Huntsman Cancer Institute, Presidential Endowed Chair of Cancer Research , Co-Leader, HCI Experimental Therapeutics Program, Director, Center of Investigational Therapeutics, Director, Genitourinary Oncology Program, Huntsman Cancer Institute, University of Utah, discuss clinical progress in prostate cancer

Featured Videos

Andrew X. Zhu, MD, PhD, on ivosidenib as a 1st line therapy for patients with CCA & an IDH1 mutation

Geoffrey Ku, MD, considers the mechanism of action and future development of zanidatamab

Mary J. Fidler, MD, regarding the role of trilaciclib as a supportive care agent for SCLC patients